Description: LungLife AI, Inc., a cancer diagnostics company, develops clinical diagnostic solutions for lung cancer with artificial intelligence (AI) technology. It engages in developing LungLB, an AI enhanced, blood-based test to utilize machine learning to identify and count CTCs with reducing operator hands-on time and increasing test performance. The company was formerly known as Cynvenio Biosystems, Inc. and changed its name to LungLife AI, Inc. in May 2019. The company is based in Thousand Oaks, California.
Home Page: lunglifeai.com
LLAI Technical Analysis
2545 West Hillcrest Drive
Thousand Oaks,
CA
91320
United States
Phone:
805 409 9868
Officers
| Name | Title |
|---|---|
| Dr. Paul Pagano Ph.D. | CEO, Chief Scientific Officer & Exec. Director |
| Mr. David M. Anderson | CFO & Exec. Director |
Exchange: LSE
Country: UK
Currency: Pence sterling (p)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.9861 |
| Price-to-Sales TTM: | 226.2469 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 14 |